California Public Employees Retirement System Raises Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

California Public Employees Retirement System boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Rating) by 57.8% during the second quarter, Holdings Channel.com reports. The firm owned 93,919 shares of the biopharmaceutical company’s stock after purchasing an additional 34,413 shares during the quarter. California Public Employees Retirement System’s holdings in Intra-Cellular Therapies were worth $5,361,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund acquired a new position in shares of Intra-Cellular Therapies during the second quarter worth $576,000. Strs Ohio increased its position in Intra-Cellular Therapies by 139.5% during the 2nd quarter. Strs Ohio now owns 30,900 shares of the biopharmaceutical company’s stock valued at $1,763,000 after buying an additional 18,000 shares in the last quarter. US Bancorp DE raised its stake in Intra-Cellular Therapies by 93.8% in the second quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 240 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in Intra-Cellular Therapies in the first quarter worth about $467,000. Finally, Victory Capital Management Inc. grew its stake in shares of Intra-Cellular Therapies by 21.7% during the second quarter. Victory Capital Management Inc. now owns 1,134,850 shares of the biopharmaceutical company’s stock worth $64,777,000 after acquiring an additional 202,528 shares during the last quarter. Hedge funds and other institutional investors own 85.48% of the company’s stock.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $51.19 on Friday. The business’s 50-day moving average is $47.95 and its two-hundred day moving average is $52.35. The company has a market capitalization of $4.85 billion, a P/E ratio of -15.42 and a beta of 1.15. Intra-Cellular Therapies, Inc. has a fifty-two week low of $34.43 and a fifty-two week high of $66.00.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 65,164 shares of the stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $45.63, for a total transaction of $2,973,433.32. The sale was disclosed in a filing with the SEC, which is available through this link. 3.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ITCI shares. Mizuho reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, October 3rd. Canaccord Genuity Group lifted their price objective on shares of Intra-Cellular Therapies from $90.00 to $93.00 in a research note on Friday, November 4th. StockNews.com raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Needham & Company LLC boosted their price objective on shares of Intra-Cellular Therapies from $65.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, August 10th. Finally, The Goldman Sachs Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $64.00 to $49.00 in a report on Monday, August 22nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies has an average rating of “Moderate Buy” and a consensus price target of $67.50.

About Intra-Cellular Therapies

(Get Rating)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.

Further Reading

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Rating).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.